DVY vs XBI
iShares Select Dividend ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.38% for DVY.
- • DVY pays a higher dividend yield (3.38%).
Side-by-side metrics
| Metric | DVY | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.38% | 0.35% |
Dividend yield Trailing 12-month yield. | 3.38% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $22.86B | $8.30B |
YTD return | 9.91% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.64 | 1.09 |
P/E ratio | 15.44 | — |
Last price | $152.45 | $133.66 |
Inception | — | — |
Issuer | iShares | State Street |
DVY top holdings
| MO | Altria Group Inc | 2.29% |
| PFE | Pfizer Inc | 2.22% |
| TROW | T. Rowe Price Group Inc | 2.02% |
| VZ | Verizon Communications Inc | 1.85% |
| PRU | Prudential Financial Inc | 1.84% |
| OKE | ONEOK Inc | 1.83% |
| HPQ | HP Inc | 1.61% |
| EIX | Edison International | 1.53% |
| LYB | LyondellBasell Industries NV Class A | 1.53% |
| GIS | General Mills Inc | 1.52% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About DVY
DVY (iShares Select Dividend ETF) is 100 high-dividend-yielding US stocks. Managed by iShares, the fund carries $22.9B in assets under management, an expense ratio of 0.38%, a dividend yield of 3.38%. Its largest holding is Altria Group Inc (MO), which represents 2.3% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 9.4%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.